Mouse Anti-CMTM5 Recombinant Antibody (CBFYC-1978) (V2LY-1206-LY373)

Li, L., Hu, Y., Chen, D., Zhu, J., Bao, W., Xu, X., ... & Feng, R. (2022). CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway. Molecular Medicine Reports, 25(1), 1-10.

Yuan, Y., Sheng, Z., Liu, Z., Zhang, X., Xiao, Y., Xie, J., ... & Xu, T. (2020). CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells. Journal of Cancer, 11(13), 3762.

Zhou, J., Lei, J., Wang, J., Lian, C. L., Hua, L., He, Z. Y., & Wu, S. G. (2020). Bioinformatics-based discovery of CKLF-Like MARVEL transmembrane member 5 as a novel biomarker for breast cancer. Frontiers in Cell and Developmental Biology, 361.

Wu, J. (2020). CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma. Cancer Biomarkers, 29(1), 89-99.

Zhang, J. W., Liu, T. F., Chen, X. H., Liang, W. Y., Feng, X. R., Wang, L., ... & Liu, M. L. (2017). Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function. Gene, 624, 56-65.

Xu, G., & Dang, C. (2017). CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer cell international, 17(1), 1-10.

Cai, B., Xiao, Y., Li, Y., & Zheng, S. (2017). CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis. Oncology letters, 14(2), 1536-1542.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols